Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BWAIN

Financiado

Black Widow Antivenom Innovation Necessity

Widow spiders are spread worldwide, and their bite induces severe envenomation symptoms that can lead to a complex syndrome known as latrodectism and death in severe cases. The only available specific treatment consists of polyclo... ver más

31/10/2023

TECHNICAL UNIVERSI...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-31

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

TECHNICAL UNIVERSITY OF DENM...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2010-17373 VENOMICA TRASLACIONAL 460K€ Cerrado

BCELLMECHANICS Regulation of antibody responses by B cell mechanical activi... 2M€ Cerrado

PRE2020-095004 BLOQUEAR LA ENTRADA DE VIRUS CON ENVUELTA EN CELULAS INMUNES... 99K€ Cerrado

RYC-2013-13138 Study of the immunological mechanisms involved in drug hyper... 309K€ Cerrado

BFU2009-07206 BASES CELULARES Y MOLECULARES DEL EFECTO DE LAS ENTEROTOXINA... 237K€ Cerrado

CNS2023-145619 Herramientas diagnósticas, pronósticas y terapéuticas 195K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2022-04-27
Fecha Fin: 2023-10-31

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Widow spiders are spread worldwide, and their bite induces severe envenomation symptoms that can lead to a complex syndrome known as latrodectism and death in severe cases. The only available specific treatment consists of polyclonal antibodies derived from horse plasma obtained by hyperimmunization with black widow spider venom. However, this process is slow, dangerous, and implies the continuous use of large domestic animals (mainly horses) in the manufacturing process. Venom unavailability is a significant supply chain bottleneck in antivenom manufacture, which imposes a very high product cost. Also, the efficacy of this horse-derived product suffers from batch-to-batch variation, resulting in variable efficacy profiles for different batches. Finally, the non-human nature of the horse-derived antibodies may provoke severe adverse immunological reactions. The high prevalence of adverse reactions severely limits its use, and antivenom use is thus reserved for only the most extreme cases, while not being administered at all to the many patients with asthma, atopy, or other allergy-related conditions. We are developing a recombinant antivenom based on a single broadly-neutralizing fully human monoclonal antibody that can neutralize the toxic effects of widow spider bites. According to WHO nomenclature, this antibody will be called Latrotoxumab, and it will be safer to administer, more efficacious, as well as cost-competitive with existing antivenoms. In this ERC PoC project, which is based on results obtained in the ERC StG project MABSTER (grant number 850974), we will explore the commercial potential of Latrotoxumab and lay the first foundation for a spin-off company (Fang Pharma) by securing in vivo PoC, securing IPR, developing a regulatory, manufacturing, and clinical trial plan, and preparing a fully-flexed business plan, incl. market, pricing, and SWOT analyses, identification of business growth opportunities (partners and investors), and exit strategy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores